Effects of interleukin-12 in the long-term protection conferred by a Mycobacterium avium subunit vaccine.
The effects of the addition of recombinant interleukin (IL)-12 to a mycobacterial subunit vaccine were analyzed in terms of the longevity of the protective immunity generated. BALB/c mice were immunized with culture filtrate proteins from Mycobacterium avium with dimethyl-dioctadecilammonium bromide (DDA) as an adjuvant. This subunit vaccine induced protection against a challenge by M. avium which lasted for at least 6 months while waning with time until 1 year postvaccination. Whereas the addition of IL-12 enhanced the initial protective efficacy of this subunit vaccine during the first 6 months, it accelerated the loss of protective efficacy observed at 1 year postvaccination. These data confirm the adjuvant properties of IL-12 in vaccines against mycobacteria and raise the possibility of late counter-protective untoward effects.
Silva
R A
RA
Laboratory of Microbiology and Immunology of Infection, Institute for Molecular and Cell Biology, University of Porto, Portugal, Rua do Campo Alegre 823, 4150-180 Porto, Portugal.
Pais
T F
TF
Appelberg
R
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D018664:Interleukin-12 / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009162:Mycobacterium avium / Q000276:immunology*; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D013997:Time Factors; D014376:Tuberculosis / Q000517:prevention & control*; D014611:Vaccination; D022223:Vaccines, Subunit / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D004338:Drug Combinations; D000644:Quaternary Ammonium Compounds; D022223:Vaccines, Subunit; D018664:Interleukin-12; C015831:dimethyldioctadecylammonium